已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure

医学 危险系数 内科学 置信区间 射血分数 安慰剂 比例危险模型 心力衰竭 随机对照试验 人口 替代医学 环境卫生 病理
作者
Muthiah Vaduganathan,Brian Claggett,Ian J. Kulac,Zi Michael Miao,Akshay S. Desai,Pardeep S. Jhund,Alasdair Henderson,Meike Brinker,James Lay‐Flurrie,Prabhakar Viswanathan,Markus F. Scheerer,Andrea Lage,Carolyn S.P. Lam,Michele Senni,Sanjiv J. Shah,Adriaan A. Voors,Faı̈ez Zannad,Bertram Pitt,John J.V. McMurray,Scott D. Solomon
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:151 (2): 149-158 被引量:9
标识
DOI:10.1161/circulationaha.124.072055
摘要

BACKGROUND: Patients with heart failure (HF) with mildly reduced or preserved ejection fraction face heightened long-term risks of morbidity and mortality. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and the nonsteroidal mineralocorticoid receptor antagonist finerenone have both been shown to reduce the risk of cardiovascular events in this population, but the effects of their combined use are not known. METHODS: FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure) was a randomized, double-blind, placebo-controlled trial of finerenone in patients with HF and left ventricular ejection fraction ≥40%. Baseline SGLT2i use was a prespecified subgroup. The primary outcome was a composite of total (first and recurrent) worsening HF events and cardiovascular death. We first assessed for evidence of treatment heterogeneity on the basis of baseline SGLT2i use. We further examined SGLT2i uptake during the trial and evaluated the treatment effects of finerenone accounting for baseline and during-trial use of SGLT2i in time-varying analyses. RESULTS: Among 6001 participants, 817 (13.6%) were treated with an SGLT2i at baseline. During 2.6 years median follow-up, treatment with finerenone similarly reduced the risk of the primary outcome in participants treated with an SGLT2i (rate ratio, 0.83 [95% CI, 0.60–1.16]) and without an SGLT2i at baseline (rate ratio, 0.85 [95% CI, 0.74–0.98]; P interaction =0.76). In follow-up, 980 participants initiated SGLT2i, which was less frequent in the finerenone arm compared with placebo (17.7% versus 20.1%; hazard ratio, 0.86 [95% CI, 0.76–0.97]). Time-updated analyses accounting for baseline and subsequent use of SGLT2i did not meaningfully alter the treatment effects of finerenone on the primary end point. CONCLUSIONS: The treatment benefits of the nonsteroidal mineralocorticoid receptor antagonist finerenone were observed irrespective of concomitant use of an SGLT2i. These data suggest that the combined use of SGLT2i and a nonsteroidal mineralocorticoid receptor antagonist may provide additive protection against cardiovascular events in patients with HF with mildly reduced or preserved ejection fraction. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04435626.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
napnap完成签到 ,获得积分10
2秒前
None完成签到 ,获得积分10
2秒前
极地东风完成签到,获得积分10
5秒前
整齐谷芹完成签到,获得积分10
7秒前
深海之镜完成签到,获得积分10
8秒前
林洁佳发布了新的文献求助10
9秒前
9秒前
Alvess完成签到 ,获得积分10
11秒前
整齐谷芹发布了新的文献求助30
13秒前
14秒前
17秒前
Ning完成签到,获得积分10
19秒前
桐桐应助科研通管家采纳,获得30
20秒前
量子星尘发布了新的文献求助10
20秒前
完美世界应助科研通管家采纳,获得10
20秒前
CodeCraft应助科研通管家采纳,获得10
20秒前
星辰大海应助科研通管家采纳,获得10
20秒前
Liu应助科研通管家采纳,获得10
20秒前
Owen应助科研通管家采纳,获得10
20秒前
20秒前
竹萧发布了新的文献求助10
21秒前
21秒前
纯真衬衫关注了科研通微信公众号
23秒前
ziyewutong完成签到,获得积分10
24秒前
25秒前
25秒前
25秒前
25秒前
万卷书完成签到 ,获得积分10
26秒前
aslink完成签到,获得积分10
27秒前
CHEN发布了新的文献求助10
27秒前
28秒前
花花521完成签到,获得积分10
28秒前
沉默小博发布了新的文献求助20
30秒前
重重发布了新的文献求助10
30秒前
可耐的青雪完成签到,获得积分10
30秒前
有趣的银完成签到,获得积分10
31秒前
英姑应助可耐的青雪采纳,获得10
34秒前
35秒前
吴嘉浩完成签到,获得积分10
37秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976572
求助须知:如何正确求助?哪些是违规求助? 3520659
关于积分的说明 11204365
捐赠科研通 3257284
什么是DOI,文献DOI怎么找? 1798667
邀请新用户注册赠送积分活动 877835
科研通“疑难数据库(出版商)”最低求助积分说明 806577